JP2022020003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022020003A5 JP2022020003A5 JP2021197736A JP2021197736A JP2022020003A5 JP 2022020003 A5 JP2022020003 A5 JP 2022020003A5 JP 2021197736 A JP2021197736 A JP 2021197736A JP 2021197736 A JP2021197736 A JP 2021197736A JP 2022020003 A5 JP2022020003 A5 JP 2022020003A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally substituted
- pharmaceutical combination
- alkyl
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258211P | 2015-11-20 | 2015-11-20 | |
| US62/258,211 | 2015-11-20 | ||
| JP2018526088A JP7017509B2 (ja) | 2015-11-20 | 2016-11-09 | がんを治療するための四環式キノロン類似体の併用療法 |
| PCT/US2016/061176 WO2017087235A1 (en) | 2015-11-20 | 2016-11-09 | Combination therapy of tetracyclic quinolone analogs for treating cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526088A Division JP7017509B2 (ja) | 2015-11-20 | 2016-11-09 | がんを治療するための四環式キノロン類似体の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022020003A JP2022020003A (ja) | 2022-01-27 |
| JP2022020003A5 true JP2022020003A5 (enExample) | 2022-03-11 |
Family
ID=58717690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526088A Active JP7017509B2 (ja) | 2015-11-20 | 2016-11-09 | がんを治療するための四環式キノロン類似体の併用療法 |
| JP2021197736A Withdrawn JP2022020003A (ja) | 2015-11-20 | 2021-12-06 | がんを治療するための四環式キノロン類似体の併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526088A Active JP7017509B2 (ja) | 2015-11-20 | 2016-11-09 | がんを治療するための四環式キノロン類似体の併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10857156B2 (enExample) |
| EP (1) | EP3377068B1 (enExample) |
| JP (2) | JP7017509B2 (enExample) |
| KR (2) | KR20180113976A (enExample) |
| CN (2) | CN119185322A (enExample) |
| AU (3) | AU2016355268B2 (enExample) |
| CA (1) | CA3005730A1 (enExample) |
| IL (1) | IL259423A (enExample) |
| RU (1) | RU2752506C2 (enExample) |
| TW (1) | TWI730013B (enExample) |
| WO (1) | WO2017087235A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CA3005730A1 (en) | 2015-11-20 | 2017-05-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018057834A1 (en) * | 2016-09-23 | 2018-03-29 | The Johns Hopkins University | Combinatory treatment strategies of cancer based on rna polymerase i inhibition |
| US11912706B2 (en) | 2017-03-28 | 2024-02-27 | Pimera, Inc. | Crystal forms of a POL1 inhibitor |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| EP3749352A1 (en) * | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| TWI884912B (zh) * | 2018-02-15 | 2025-06-01 | 生華生物科技股份有限公司 | 喹啉酮類似物及其鹽、組合物及其使用方法 |
| JP7154634B2 (ja) * | 2018-03-13 | 2022-10-18 | 国立大学法人大阪大学 | 腫瘍免疫賦活剤 |
| CA3093851A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| GB201816825D0 (en) * | 2018-10-16 | 2018-11-28 | Phoremost Ltd | Target for anti-cancer therapy |
| WO2020114518A1 (zh) * | 2018-12-07 | 2020-06-11 | 科济生物医药（上海）有限公司 | 肿瘤联合免疫治疗 |
| CA3129585A1 (en) * | 2019-02-18 | 2020-08-27 | Medivir Aktiebolag | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| CN110075061A (zh) * | 2019-03-13 | 2019-08-02 | 安庆瑄宇医药科技有限公司 | 一种尼拉帕尼口服液及其制备方法 |
| BR112022002784A2 (pt) * | 2019-08-14 | 2022-08-09 | Senhwa Biosciences Inc | Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo |
| JP2023509191A (ja) * | 2020-01-09 | 2023-03-07 | アストラゼネカ・アクチエボラーグ | 癌を治療するための組み合わせ療法 |
| CN113491768A (zh) * | 2020-04-01 | 2021-10-12 | 深圳市罗湖区人民医院 | Cd137抗体在制备促进nk细胞表达cd16分子的药物中的应用 |
| TW202227082A (zh) * | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 用於治療癌症之組合療法 |
| CN114409681A (zh) * | 2022-03-18 | 2022-04-29 | 信义核新(北京)生物科技有限公司 | 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用 |
| CN115160341B (zh) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
| AU2023334696A1 (en) * | 2022-08-30 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN116063328B (zh) * | 2023-03-29 | 2023-06-20 | 信义核新(北京)生物科技有限公司 | 一种四环喹诺酮化合物、药学上可接受的盐及其应用 |
| EP4703365A1 (en) * | 2023-04-23 | 2026-03-04 | Horizon Omics Biotech Limited | Quinolone derivative and use thereof against tumors |
| WO2024242545A1 (ko) * | 2023-05-23 | 2024-11-28 | (주) 메티메디제약 | 칼슘 락테이트를 활성 성분으로 포함하는 암 백신 조성물 및 그 용도 |
| WO2025101688A1 (en) * | 2023-11-08 | 2025-05-15 | Mary Hitchcock Memorial Hospital For Itself And On Behalf Of Dartmouth-Hitchcock Clinic (Collectively Doing Business As Dartmouth-Hitchcock) | Combination therapy using tetrathiomolybdate |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE60011755T2 (de) | 1999-04-07 | 2005-06-30 | The University Of Virginia Patent Foundation | Calciumkanalblocker als antikrebsmittel |
| WO2003050107A1 (en) | 2001-12-13 | 2003-06-19 | Wockhardt Limited | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| US6900224B2 (en) | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| AU2004220321B2 (en) * | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
| PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
| CN1997642B (zh) | 2003-09-22 | 2012-06-13 | 詹森药业有限公司 | 7-氨基亚烷基-杂环喹诺酮类和萘啶酮类 |
| TWI338000B (en) | 2003-12-01 | 2011-03-01 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| EP1761540B1 (en) * | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| EP1802306A2 (en) | 2004-09-17 | 2007-07-04 | Cylene Pharmaceuticals, Inc. | Quinolone analog as cell proliferation inhibitors |
| US7816524B2 (en) | 2005-08-05 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Methods of preparing quinolone analogs |
| US20070117770A1 (en) | 2005-08-19 | 2007-05-24 | Cylene Pharmaceuticals, Inc. | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof |
| AR057555A1 (es) | 2005-10-27 | 2007-12-05 | Merck Frosst Canada Ltd | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo |
| WO2007056113A2 (en) | 2005-11-02 | 2007-05-18 | Cylene Pharmaceuticals, Inc. | Methods for targeting quadruplex sequences |
| WO2008060693A2 (en) | 2006-05-17 | 2008-05-22 | Cylene Pharmaceuticals, Inc. | Tetracyclic imidazole analogs |
| WO2007146831A2 (en) | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide |
| US20110112086A1 (en) | 2006-06-08 | 2011-05-12 | Cylene Pharmaceuticals, Inc. | Pyridinone analogs |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US20110065687A1 (en) | 2007-04-17 | 2011-03-17 | Michael Schwaebe | Hydrazide compounds and uses thereof |
| CN101888780B (zh) | 2007-10-05 | 2014-08-13 | 生华生物科技股份有限公司 | 喹诺酮类似物及其相关方法 |
| AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| PE20091924A1 (es) | 2008-05-14 | 2010-01-04 | Takeda Pharmaceutical | Compuesto peptidico y su uso |
| EP2683825B1 (en) * | 2011-03-11 | 2017-01-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
| WO2012123938A1 (en) | 2011-03-17 | 2012-09-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| CA2892371C (en) * | 2011-12-01 | 2021-01-19 | The Brigham And Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
| WO2013133876A1 (en) | 2011-12-07 | 2013-09-12 | The Regents Of The University Of California | Biomarkers for prediction of response to parp inhibition in breast cancer |
| US9044421B2 (en) * | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| EP3834838A1 (en) | 2014-02-21 | 2021-06-16 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody |
| CA3005730A1 (en) | 2015-11-20 | 2017-05-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| US9957282B2 (en) | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| TWI884912B (zh) | 2018-02-15 | 2025-06-01 | 生華生物科技股份有限公司 | 喹啉酮類似物及其鹽、組合物及其使用方法 |
| BR112022002784A2 (pt) | 2019-08-14 | 2022-08-09 | Senhwa Biosciences Inc | Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo |
| BR112022002772A2 (pt) | 2019-08-14 | 2022-08-09 | Senhwa Biosciences Inc | Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso |
-
2016
- 2016-11-09 CA CA3005730A patent/CA3005730A1/en not_active Abandoned
- 2016-11-09 EP EP16866873.9A patent/EP3377068B1/en active Active
- 2016-11-09 CN CN202411002530.XA patent/CN119185322A/zh active Pending
- 2016-11-09 RU RU2018122172A patent/RU2752506C2/ru active
- 2016-11-09 KR KR1020187017359A patent/KR20180113976A/ko not_active Ceased
- 2016-11-09 TW TW105136510A patent/TWI730013B/zh active
- 2016-11-09 AU AU2016355268A patent/AU2016355268B2/en active Active
- 2016-11-09 KR KR1020257014594A patent/KR20250065935A/ko active Pending
- 2016-11-09 CN CN201680075438.3A patent/CN108601789A/zh active Pending
- 2016-11-09 US US15/347,656 patent/US10857156B2/en active Active
- 2016-11-09 JP JP2018526088A patent/JP7017509B2/ja active Active
- 2016-11-09 WO PCT/US2016/061176 patent/WO2017087235A1/en not_active Ceased
-
2018
- 2018-05-16 IL IL259423A patent/IL259423A/en unknown
-
2019
- 2019-01-18 US US16/251,866 patent/US11229654B2/en active Active
-
2020
- 2020-09-28 US US17/034,578 patent/US20210113584A1/en active Pending
-
2021
- 2021-08-31 AU AU2021225157A patent/AU2021225157B2/en active Active
- 2021-12-06 JP JP2021197736A patent/JP2022020003A/ja not_active Withdrawn
- 2021-12-06 US US17/543,383 patent/US20220088029A1/en not_active Abandoned
-
2023
- 2023-09-13 AU AU2023229524A patent/AU2023229524B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
| JP2023512038A5 (enExample) | ||
| JP2025065346A5 (ja) | 組み合わせ物 | |
| JP2018534321A5 (enExample) | ||
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| JP2019510832A5 (enExample) | ||
| US12350265B2 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | |
| JPWO2021060453A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| BR112013025386B1 (pt) | Uso de um composto, combinação, medicamento, produto e sistema | |
| JP2014509658A (ja) | ガン処置方法 | |
| BR112021006033A2 (pt) | Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina | |
| JP2018510869A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JPWO2020032105A5 (enExample) | ||
| CN109789127A (zh) | 吲哚啉酮化合物的用途 | |
| CN102264368A (zh) | 极光激酶抑制剂与抗cd20抗体的组合 | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP7713619B2 (ja) | 大員環分子およびそれらの使用 | |
| ES3032458T3 (en) | Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | |
| ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
| AU2014280354A1 (en) | Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor | |
| JP2014512362A5 (enExample) | ||
| ES2982346T3 (es) | Sales metálicas y usos de las mismas |